Sharda Cropchem Ltd · SHARDACROP · Pesticides/Agrochemicals · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 2 November 2026
Sharda Cropchem share price today: ₹698.75 at the close on 18 November 2026, down 12.6% in a year. Sharda Cropchem (SHARDACROP) is worth ₹6,309 crore, trades at a P/E of 9.8 and has closed between ₹642.60 and ₹1,256.00 over the past 52 weeks. Latest change: revenue up on a year earlier for 10 quarters in a row.
Sharda Cropchem Ltd's earnings have grown faster than its share price. Earnings per share grew +42.4% in a year while the price moved −12.6%.
The main question: earnings per share (last four quarters) moved +42.4% while the share price moved −12.6%.
The price has been falling for 18 weeks, and the P/E is lower than 98% of its own last 11 years. Over the last four quarters, results have been improving, with profit +24.3% on a year earlier, and 157% of the last 3 years' profit came in as cash. What will decide it: whether the price catches up with earnings that have already grown.
What is the Sharda Cropchem share price today?
Sharda Cropchem Ltd's share price was ₹698.75 at the close on 18 November 2026. It has been falling for 18 weeks. That is 15.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹643 and ₹1,256, and at that close it sat 9% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sharda Cropchem Ltd is in stage 4. The phase helps read everything below.
Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 35 weeks running.
Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 233 of 554 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 26 Feb 2016 | no NIFTY 500 reading |
| 4 Mar 2016 | no NIFTY 500 reading |
| 11 Mar 2016 | no NIFTY 500 reading |
| 18 Mar 2016 | no NIFTY 500 reading |
| 23 Mar 2016 | no NIFTY 500 reading |
| 1 Apr 2016 | no NIFTY 500 reading |
| 8 Apr 2016 | no NIFTY 500 reading |
| 13 Apr 2016 | no NIFTY 500 reading |
| 22 Apr 2016 | no NIFTY 500 reading |
| 29 Apr 2016 | no NIFTY 500 reading |
| 6 May 2016 | no NIFTY 500 reading |
| 13 May 2016 | no NIFTY 500 reading |
| 20 May 2016 | no NIFTY 500 reading |
| 27 May 2016 | +51.5% |
| 3 Jun 2016 | +55.1% |
| 10 Jun 2016 | +53.2% |
| 17 Jun 2016 | +68.4% |
| 24 Jun 2016 | +61.8% |
| 1 Jul 2016 | +52.0% |
| 8 Jul 2016 | +43.3% |
| 15 Jul 2016 | +26.4% |
| 22 Jul 2016 | +27.1% |
| 29 Jul 2016 | +34.4% |
| 5 Aug 2016 | +25.5% |
| 12 Aug 2016 | +10.4% |
| 19 Aug 2016 | +11.4% |
| 26 Aug 2016 | −1.1% |
| 2 Sep 2016 | −11.8% |
| 9 Sep 2016 | −12.7% |
| 16 Sep 2016 | −17.1% |
| 23 Sep 2016 | −3.0% |
| 30 Sep 2016 | −6.3% |
| 7 Oct 2016 | +5.1% |
| 14 Oct 2016 | +9.9% |
| 21 Oct 2016 | +10.2% |
| 30 Oct 2016 | +10.1% |
| 4 Nov 2016 | +9.7% |
| 11 Nov 2016 | +15.3% |
| 18 Nov 2016 | +14.9% |
| 25 Nov 2016 | +11.7% |
| 2 Dec 2016 | +25.0% |
| 9 Dec 2016 | +24.8% |
| 16 Dec 2016 | +30.5% |
| 23 Dec 2016 | +19.5% |
| 30 Dec 2016 | +21.8% |
| 6 Jan 2017 | +18.5% |
| 13 Jan 2017 | +13.8% |
| 20 Jan 2017 | +13.5% |
| 27 Jan 2017 | +10.3% |
| 3 Feb 2017 | +18.2% |
| 10 Feb 2017 | +14.9% |
| 17 Feb 2017 | +9.2% |
| 23 Feb 2017 | +7.0% |
| 3 Mar 2017 | −2.5% |
| 10 Mar 2017 | +0.3% |
| 17 Mar 2017 | −10.1% |
| 24 Mar 2017 | −13.5% |
| 31 Mar 2017 | −4.7% |
| 7 Apr 2017 | −9.9% |
| 13 Apr 2017 | −8.2% |
| 21 Apr 2017 | +0.7% |
| 28 Apr 2017 | −5.1% |
| 5 May 2017 | −5.3% |
| 12 May 2017 | +1.4% |
| 19 May 2017 | +9.5% |
| 26 May 2017 | +1.2% |
| 2 Jun 2017 | −0.7% |
| 9 Jun 2017 | −3.5% |
| 16 Jun 2017 | −1.0% |
| 23 Jun 2017 | +1.3% |
| 30 Jun 2017 | −5.7% |
| 7 Jul 2017 | −7.6% |
| 14 Jul 2017 | −8.3% |
| 21 Jul 2017 | −15.3% |
| 28 Jul 2017 | −9.8% |
| 4 Aug 2017 | −19.1% |
| 11 Aug 2017 | −19.6% |
| 18 Aug 2017 | −24.2% |
| 24 Aug 2017 | −13.8% |
| 1 Sep 2017 | −16.9% |
| 8 Sep 2017 | −15.1% |
| 15 Sep 2017 | −11.8% |
| 22 Sep 2017 | −14.7% |
| 29 Sep 2017 | −11.0% |
| 6 Oct 2017 | −9.3% |
| 13 Oct 2017 | −10.3% |
| 19 Oct 2017 | −9.4% |
| 27 Oct 2017 | −12.9% |
| 3 Nov 2017 | −7.5% |
| 10 Nov 2017 | −9.6% |
| 17 Nov 2017 | −3.8% |
| 24 Nov 2017 | −3.4% |
| 1 Dec 2017 | +4.9% |
| 8 Dec 2017 | +0.3% |
| 15 Dec 2017 | −2.5% |
| 22 Dec 2017 | −2.6% |
| 29 Dec 2017 | −8.7% |
| 5 Jan 2018 | −5.9% |
| 12 Jan 2018 | −7.4% |
| 19 Jan 2018 | −9.8% |
| 25 Jan 2018 | −5.3% |
| 2 Feb 2018 | −6.9% |
| 9 Feb 2018 | −14.2% |
| 16 Feb 2018 | −13.5% |
| 23 Feb 2018 | −17.0% |
| 1 Mar 2018 | −18.7% |
| 9 Mar 2018 | −14.8% |
| 16 Mar 2018 | −15.8% |
| 23 Mar 2018 | −13.8% |
| 28 Mar 2018 | −9.2% |
| 6 Apr 2018 | −9.2% |
| 13 Apr 2018 | −9.9% |
| 20 Apr 2018 | −4.2% |
| 27 Apr 2018 | −6.3% |
| 4 May 2018 | −4.4% |
| 11 May 2018 | +9.9% |
| 18 May 2018 | +10.2% |
| 25 May 2018 | +5.3% |
| 1 Jun 2018 | +6.2% |
| 8 Jun 2018 | +0.9% |
| 15 Jun 2018 | +0.8% |
| 22 Jun 2018 | −0.5% |
| 29 Jun 2018 | −13.7% |
| 6 Jul 2018 | −17.0% |
| 13 Jul 2018 | −12.6% |
| 20 Jul 2018 | −18.0% |
| 27 Jul 2018 | −10.0% |
| 3 Aug 2018 | −11.7% |
| 10 Aug 2018 | −8.4% |
| 17 Aug 2018 | −15.0% |
| 24 Aug 2018 | −9.4% |
| 31 Aug 2018 | −13.0% |
| 7 Sep 2018 | −7.7% |
| 14 Sep 2018 | −9.6% |
| 21 Sep 2018 | −12.6% |
| 28 Sep 2018 | −2.1% |
| 5 Oct 2018 | +9.1% |
| 12 Oct 2018 | +2.6% |
| 19 Oct 2018 | +5.2% |
| 26 Oct 2018 | +2.0% |
| 2 Nov 2018 | −5.7% |
| 9 Nov 2018 | −12.8% |
| 16 Nov 2018 | −13.1% |
| 22 Nov 2018 | −14.8% |
| 30 Nov 2018 | −17.5% |
| 7 Dec 2018 | −21.8% |
| 14 Dec 2018 | −22.5% |
| 21 Dec 2018 | −1.8% |
| 28 Dec 2018 | −7.6% |
| 4 Jan 2019 | −15.9% |
| 11 Jan 2019 | −12.0% |
| 18 Jan 2019 | −10.8% |
| 25 Jan 2019 | −15.4% |
| 1 Feb 2019 | +0.8% |
| 8 Feb 2019 | −1.1% |
| 15 Feb 2019 | +4.4% |
| 22 Feb 2019 | +14.8% |
| 1 Mar 2019 | +23.4% |
| 8 Mar 2019 | +33.0% |
| 15 Mar 2019 | +33.1% |
| 22 Mar 2019 | +6.2% |
| 29 Mar 2019 | +14.8% |
| 5 Apr 2019 | +17.9% |
| 12 Apr 2019 | +25.0% |
| 18 Apr 2019 | +18.8% |
| 26 Apr 2019 | +15.2% |
| 3 May 2019 | +18.2% |
| 10 May 2019 | +17.9% |
| 17 May 2019 | +1.6% |
| 24 May 2019 | −6.5% |
| 31 May 2019 | −11.3% |
| 7 Jun 2019 | −8.2% |
| 14 Jun 2019 | −7.6% |
| 21 Jun 2019 | −13.0% |
| 28 Jun 2019 | −14.9% |
| 5 Jul 2019 | −17.8% |
| 12 Jul 2019 | −19.7% |
| 19 Jul 2019 | −13.7% |
| 26 Jul 2019 | −20.0% |
| 2 Aug 2019 | −27.1% |
| 9 Aug 2019 | −18.3% |
| 16 Aug 2019 | −11.2% |
| 23 Aug 2019 | −13.9% |
| 30 Aug 2019 | −13.5% |
| 6 Sep 2019 | −12.9% |
| 13 Sep 2019 | −7.7% |
| 20 Sep 2019 | −2.9% |
| 27 Sep 2019 | −1.7% |
| 4 Oct 2019 | −3.1% |
| 11 Oct 2019 | −9.8% |
| 18 Oct 2019 | −11.9% |
| 27 Oct 2019 | −3.0% |
| 1 Nov 2019 | −4.2% |
| 8 Nov 2019 | −17.8% |
| 15 Nov 2019 | −20.1% |
| 22 Nov 2019 | −28.8% |
| 29 Nov 2019 | −32.7% |
| 6 Dec 2019 | −34.5% |
| 13 Dec 2019 | −34.3% |
| 20 Dec 2019 | −34.2% |
| 27 Dec 2019 | −34.9% |
| 3 Jan 2020 | −8.8% |
| 10 Jan 2020 | −17.2% |
| 17 Jan 2020 | −5.1% |
| 24 Jan 2020 | −15.5% |
| 1 Feb 2020 | −19.1% |
| 7 Feb 2020 | −18.2% |
| 14 Feb 2020 | −18.7% |
| 20 Feb 2020 | −6.9% |
| 28 Feb 2020 | +4.4% |
| 6 Mar 2020 | +5.5% |
| 13 Mar 2020 | −5.1% |
| 20 Mar 2020 | −14.9% |
| 27 Mar 2020 | −19.8% |
| 3 Apr 2020 | −30.5% |
| 9 Apr 2020 | −18.5% |
| 17 Apr 2020 | −24.4% |
| 24 Apr 2020 | −20.7% |
| 30 Apr 2020 | −16.8% |
| 8 May 2020 | −15.4% |
| 15 May 2020 | −9.5% |
| 22 May 2020 | −10.5% |
| 29 May 2020 | −8.6% |
| 5 Jun 2020 | −3.4% |
| 12 Jun 2020 | +2.7% |
| 19 Jun 2020 | +38.9% |
| 26 Jun 2020 | +99.3% |
| 3 Jul 2020 | +109.0% |
| 10 Jul 2020 | +78.0% |
| 17 Jul 2020 | +64.5% |
| 24 Jul 2020 | +92.1% |
| 31 Jul 2020 | +88.2% |
| 7 Aug 2020 | +101.8% |
| 14 Aug 2020 | +81.1% |
| 21 Aug 2020 | +97.5% |
| 28 Aug 2020 | +63.6% |
| 4 Sep 2020 | +37.6% |
| 11 Sep 2020 | +34.8% |
| 18 Sep 2020 | +26.1% |
| 25 Sep 2020 | +0.5% |
| 1 Oct 2020 | −5.2% |
| 9 Oct 2020 | −20.8% |
| 16 Oct 2020 | −19.1% |
| 23 Oct 2020 | −15.9% |
| 30 Oct 2020 | −13.3% |
| 6 Nov 2020 | −23.7% |
| 14 Nov 2020 | −18.2% |
| 20 Nov 2020 | −24.4% |
| 27 Nov 2020 | −17.4% |
| 4 Dec 2020 | −16.1% |
| 11 Dec 2020 | −12.8% |
| 18 Dec 2020 | −18.3% |
| 24 Dec 2020 | −18.7% |
| 1 Jan 2021 | −19.3% |
| 8 Jan 2021 | −10.3% |
| 15 Jan 2021 | −8.3% |
| 22 Jan 2021 | −21.6% |
| 29 Jan 2021 | −14.1% |
| 5 Feb 2021 | −13.5% |
| 12 Feb 2021 | −8.8% |
| 19 Feb 2021 | +13.4% |
| 26 Feb 2021 | +4.1% |
| 5 Mar 2021 | +0.2% |
| 12 Mar 2021 | −2.6% |
| 19 Mar 2021 | +5.1% |
| 26 Mar 2021 | +0.8% |
| 1 Apr 2021 | +3.0% |
| 9 Apr 2021 | +6.3% |
| 16 Apr 2021 | +3.7% |
| 23 Apr 2021 | +7.5% |
| 30 Apr 2021 | −3.7% |
| 7 May 2021 | +5.7% |
| 14 May 2021 | +7.4% |
| 21 May 2021 | −6.2% |
| 28 May 2021 | −2.7% |
| 4 Jun 2021 | +3.4% |
| 11 Jun 2021 | +14.8% |
| 18 Jun 2021 | +5.8% |
| 25 Jun 2021 | +7.4% |
| 2 Jul 2021 | +12.4% |
| 9 Jul 2021 | +7.4% |
| 16 Jul 2021 | +10.3% |
| 23 Jul 2021 | +4.4% |
| 30 Jul 2021 | +5.3% |
| 6 Aug 2021 | −5.6% |
| 13 Aug 2021 | −15.2% |
| 20 Aug 2021 | −20.6% |
| 27 Aug 2021 | −16.8% |
| 3 Sep 2021 | −23.6% |
| 9 Sep 2021 | −21.6% |
| 17 Sep 2021 | −16.9% |
| 24 Sep 2021 | −17.5% |
| 1 Oct 2021 | −21.0% |
| 8 Oct 2021 | −21.8% |
| 14 Oct 2021 | −26.1% |
| 22 Oct 2021 | −22.3% |
| 29 Oct 2021 | −21.8% |
| 4 Nov 2021 | −15.8% |
| 12 Nov 2021 | −9.1% |
| 18 Nov 2021 | +0.5% |
| 26 Nov 2021 | −3.6% |
| 3 Dec 2021 | +1.9% |
| 10 Dec 2021 | −0.7% |
| 17 Dec 2021 | −2.9% |
| 24 Dec 2021 | +7.1% |
| 31 Dec 2021 | +9.3% |
| 7 Jan 2022 | +7.6% |
| 14 Jan 2022 | +14.1% |
| 21 Jan 2022 | +23.3% |
| 28 Jan 2022 | +97.7% |
| 4 Feb 2022 | +112.4% |
| 11 Feb 2022 | +76.5% |
| 18 Feb 2022 | +71.4% |
| 25 Feb 2022 | +76.1% |
| 4 Mar 2022 | +81.3% |
| 11 Mar 2022 | +68.2% |
| 17 Mar 2022 | +73.4% |
| 25 Mar 2022 | +58.7% |
| 1 Apr 2022 | +75.2% |
| 8 Apr 2022 | +101.3% |
| 13 Apr 2022 | +95.2% |
| 22 Apr 2022 | +81.7% |
| 29 Apr 2022 | +3.0% |
| 6 May 2022 | +1.4% |
| 13 May 2022 | +25.1% |
| 20 May 2022 | +31.7% |
| 27 May 2022 | +39.0% |
| 3 Jun 2022 | +28.2% |
| 10 Jun 2022 | +37.1% |
| 17 Jun 2022 | +26.4% |
| 24 Jun 2022 | +20.2% |
| 1 Jul 2022 | +10.6% |
| 8 Jul 2022 | +2.0% |
| 15 Jul 2022 | +4.9% |
| 22 Jul 2022 | +5.4% |
| 29 Jul 2022 | −15.9% |
| 5 Aug 2022 | −21.2% |
| 12 Aug 2022 | −30.9% |
| 19 Aug 2022 | −36.7% |
| 26 Aug 2022 | −37.4% |
| 2 Sep 2022 | −35.2% |
| 9 Sep 2022 | −41.2% |
| 16 Sep 2022 | −41.8% |
| 23 Sep 2022 | −38.2% |
| 30 Sep 2022 | −39.1% |
| 7 Oct 2022 | −37.4% |
| 14 Oct 2022 | −42.3% |
| 21 Oct 2022 | −40.9% |
| 28 Oct 2022 | −28.8% |
| 4 Nov 2022 | −28.6% |
| 11 Nov 2022 | −29.1% |
| 18 Nov 2022 | −27.6% |
| 25 Nov 2022 | −26.6% |
| 2 Dec 2022 | −20.7% |
| 9 Dec 2022 | −8.7% |
| 16 Dec 2022 | −0.8% |
| 23 Dec 2022 | −6.1% |
| 30 Dec 2022 | +12.1% |
| 6 Jan 2023 | +4.8% |
| 13 Jan 2023 | +4.8% |
| 20 Jan 2023 | +6.0% |
| 27 Jan 2023 | +28.3% |
| 3 Feb 2023 | +24.3% |
| 10 Feb 2023 | +24.4% |
| 17 Feb 2023 | +27.7% |
| 24 Feb 2023 | +21.7% |
| 3 Mar 2023 | +18.0% |
| 10 Mar 2023 | +4.7% |
| 17 Mar 2023 | −1.6% |
| 24 Mar 2023 | +14.4% |
| 31 Mar 2023 | +0.9% |
| 6 Apr 2023 | +2.1% |
| 13 Apr 2023 | +0.7% |
| 21 Apr 2023 | −2.7% |
| 28 Apr 2023 | −7.6% |
| 5 May 2023 | −4.0% |
| 12 May 2023 | +2.6% |
| 19 May 2023 | +2.0% |
| 26 May 2023 | −6.5% |
| 2 Jun 2023 | −5.8% |
| 9 Jun 2023 | +10.9% |
| 16 Jun 2023 | +10.0% |
| 23 Jun 2023 | +3.2% |
| 30 Jun 2023 | +0.2% |
| 7 Jul 2023 | −1.2% |
| 14 Jul 2023 | +5.6% |
| 21 Jul 2023 | −0.2% |
| 28 Jul 2023 | −14.4% |
| 4 Aug 2023 | −19.2% |
| 11 Aug 2023 | −24.4% |
| 18 Aug 2023 | −24.8% |
| 25 Aug 2023 | −17.7% |
| 1 Sep 2023 | −15.5% |
| 8 Sep 2023 | −28.0% |
| 15 Sep 2023 | −28.3% |
| 22 Sep 2023 | −26.0% |
| 29 Sep 2023 | −29.4% |
| 6 Oct 2023 | −25.4% |
| 13 Oct 2023 | −22.5% |
| 20 Oct 2023 | −16.1% |
| 27 Oct 2023 | −8.2% |
| 3 Nov 2023 | −5.6% |
| 12 Nov 2023 | −2.8% |
| 17 Nov 2023 | −3.5% |
| 24 Nov 2023 | −6.9% |
| 1 Dec 2023 | −15.1% |
| 8 Dec 2023 | −14.2% |
| 15 Dec 2023 | −10.3% |
| 22 Dec 2023 | −10.9% |
| 29 Dec 2023 | −4.6% |
| 5 Jan 2024 | −9.3% |
| 12 Jan 2024 | −14.5% |
| 20 Jan 2024 | −15.3% |
| 25 Jan 2024 | −18.1% |
| 2 Feb 2024 | −23.6% |
| 9 Feb 2024 | −25.6% |
| 16 Feb 2024 | −27.8% |
| 23 Feb 2024 | −27.4% |
| 2 Mar 2024 | −24.3% |
| 7 Mar 2024 | −26.2% |
| 15 Mar 2024 | −26.6% |
| 22 Mar 2024 | −28.2% |
| 28 Mar 2024 | −33.3% |
| 5 Apr 2024 | −22.4% |
| 12 Apr 2024 | −18.8% |
| 19 Apr 2024 | −21.7% |
| 26 Apr 2024 | −12.3% |
| 3 May 2024 | −9.9% |
| 10 May 2024 | −6.8% |
| 18 May 2024 | +7.6% |
| 24 May 2024 | +6.0% |
| 31 May 2024 | +3.0% |
| 7 Jun 2024 | +9.6% |
| 14 Jun 2024 | +19.3% |
| 21 Jun 2024 | +23.6% |
| 28 Jun 2024 | +27.7% |
| 5 Jul 2024 | +22.7% |
| 12 Jul 2024 | +21.1% |
| 19 Jul 2024 | +26.5% |
| 26 Jul 2024 | +36.2% |
| 2 Aug 2024 | +41.1% |
| 9 Aug 2024 | +41.2% |
| 16 Aug 2024 | +27.6% |
| 23 Aug 2024 | +32.3% |
| 30 Aug 2024 | +33.9% |
| 6 Sep 2024 | +29.0% |
| 13 Sep 2024 | +22.0% |
| 20 Sep 2024 | +11.9% |
| 27 Sep 2024 | +17.0% |
| 4 Oct 2024 | +12.6% |
| 11 Oct 2024 | +11.7% |
| 18 Oct 2024 | +20.1% |
| 25 Oct 2024 | +9.3% |
| 1 Nov 2024 | +35.4% |
| 8 Nov 2024 | +48.6% |
| 14 Nov 2024 | +42.1% |
| 22 Nov 2024 | +45.0% |
| 29 Nov 2024 | +47.7% |
| 6 Dec 2024 | +49.5% |
| 13 Dec 2024 | +47.5% |
| 20 Dec 2024 | +54.8% |
| 27 Dec 2024 | +47.7% |
| 3 Jan 2025 | +50.5% |
| 10 Jan 2025 | +40.7% |
| 17 Jan 2025 | +27.3% |
| 24 Jan 2025 | +8.1% |
| 1 Feb 2025 | −18.7% |
| 7 Feb 2025 | −23.4% |
| 14 Feb 2025 | −25.3% |
| 21 Feb 2025 | −27.1% |
| 28 Feb 2025 | −26.1% |
| 7 Mar 2025 | −20.3% |
| 13 Mar 2025 | −19.7% |
| 21 Mar 2025 | −21.6% |
| 28 Mar 2025 | −21.9% |
| 4 Apr 2025 | −29.8% |
| 11 Apr 2025 | −30.0% |
| 17 Apr 2025 | −21.5% |
| 25 Apr 2025 | −12.6% |
| 2 May 2025 | −5.5% |
| 9 May 2025 | −10.9% |
| 16 May 2025 | +7.7% |
| 23 May 2025 | +11.8% |
| 30 May 2025 | +34.2% |
| 6 Jun 2025 | +25.1% |
| 13 Jun 2025 | +34.8% |
| 20 Jun 2025 | +27.7% |
| 27 Jun 2025 | +27.5% |
| 4 Jul 2025 | +64.4% |
| 11 Jul 2025 | +55.1% |
| 18 Jul 2025 | +39.5% |
| 25 Jul 2025 | +92.5% |
| 1 Aug 2025 | +100.5% |
| 8 Aug 2025 | +85.1% |
| 14 Aug 2025 | +51.5% |
| 22 Aug 2025 | +47.5% |
| 29 Aug 2025 | +30.1% |
| 5 Sep 2025 | +18.6% |
| 12 Sep 2025 | +7.7% |
| 19 Sep 2025 | +11.1% |
| 26 Sep 2025 | +8.5% |
| 3 Oct 2025 | −5.1% |
| 10 Oct 2025 | −1.2% |
| 17 Oct 2025 | −5.6% |
| 24 Oct 2025 | −21.1% |
| 31 Oct 2025 | −26.5% |
| 7 Nov 2025 | −26.4% |
| 14 Nov 2025 | −24.4% |
| 21 Nov 2025 | −20.3% |
| 28 Nov 2025 | −15.7% |
| 5 Dec 2025 | −9.4% |
| 12 Dec 2025 | +1.5% |
| 19 Dec 2025 | −2.4% |
| 26 Dec 2025 | −0.9% |
| 2 Jan 2026 | −4.1% |
| 9 Jan 2026 | −3.3% |
| 16 Jan 2026 | +3.0% |
| 23 Jan 2026 | −5.2% |
| 1 Feb 2026 | +16.9% |
| 6 Feb 2026 | +54.0% |
| 13 Feb 2026 | +64.8% |
| 20 Feb 2026 | +52.1% |
| 27 Feb 2026 | +41.3% |
| 6 Mar 2026 | +26.2% |
| 13 Mar 2026 | +17.8% |
| 20 Mar 2026 | +20.6% |
| 27 Mar 2026 | +18.2% |
| 2 Apr 2026 | +16.9% |
| 10 Apr 2026 | +37.3% |
| 17 Apr 2026 | +37.1% |
| 24 Apr 2026 | +38.2% |
| 30 Apr 2026 | +10.3% |
| 8 May 2026 | −4.5% |
| 15 May 2026 | −19.5% |
| 22 May 2026 | −22.6% |
| 29 May 2026 | −21.8% |
| 4 Jun 2026 | −13.4% |
| 5 Jun 2026 | −14.8% |
| 10 Jun 2026 | −13.7% |
| 12 Jun 2026 | −6.5% |
| 17 Jun 2026 | −7.5% |
| 19 Jun 2026 | −18.4% |
| 24 Jun 2026 | −20.9% |
| 25 Jun 2026 | −23.4% |
| 1 Jul 2026 | −20.2% |
| 3 Jul 2026 | −19.7% |
| 10 Jul 2026 | −9.2% |
| 17 Jul 2026 | −2.4% |
| 24 Jul 2026 | −4.7% |
| 31 Jul 2026 | −13.8% |
| 7 Aug 2026 | −14.4% |
| 14 Aug 2026 | −17.3% |
| 21 Aug 2026 | −21.7% |
| 28 Aug 2026 | −15.9% |
| 4 Sep 2026 | −15.2% |
| 11 Sep 2026 | −12.7% |
| 18 Sep 2026 | −14.0% |
| 25 Sep 2026 | −12.3% |
| 1 Oct 2026 | −15.9% |
| 9 Oct 2026 | −14.5% |
| 16 Oct 2026 | −14.8% |
| 23 Oct 2026 | −19.9% |
| 30 Oct 2026 | −12.2% |
| 6 Nov 2026 | −14.7% |
| 8 Nov 2026 | −11.9% |
| 13 Nov 2026 | −4.9% |
| 18 Nov 2026 | −11.7% |
Over the last 11 years the share price moved +236% while the NIFTY 500 moved +306%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 April 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Sharda Cropchem this quarter?
Revenue up on a year earlier for 10 quarters in a row
In the September 2026 quarter revenue was ₹1,052 crore, +13.2% on a year earlier.
Why: Revenue rose because higher prices and currency moves, plus a better mix of products sold, more than made up for lower volumes.
Next results: check whether overall volumes return to growth.
From the earnings call on 2 Nov 2026.
What are Sharda Cropchem's latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Sharda Cropchem reported revenue of ₹1,052 crore, up 13.2% from ₹929 crore a year earlier, and a profit of ₹92.0 crore, up 24.3% from ₹74.0 crore.
Sharda Cropchem results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹1,052 crore | ₹929 crore | +13.2% |
| Profit | ₹92.0 crore | ₹74.0 crore | +24.3% |
| Earnings per share | ₹10.17 | ₹8.24 | +23.4% |
| Operating margin | 15.6% | 14.3% | +1.3 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Sharda Cropchem's management discussed these results on a call held on 2 November 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Sharda Cropchem share price history?
Sharda Cropchem closed at ₹698.75 on 18 November 2026, down 12.6% from ₹799.35 a year earlier (21 November 2025) and up 108.7% over five years. Its highest weekly close since February 2016 was ₹1,256.00 on 13 February 2026.
Sharda Cropchem share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹715.70 | −2.4% |
| 1 month ago · 19 Oct 2026 | ₹699.80 | −0.2% |
| 6 months ago · 15 May 2026 | ₹969.00 | −27.9% |
| 1 year ago · 21 Nov 2025 | ₹799.35 | −12.6% |
| 3 years ago · 17 Nov 2023 | ₹426.30 | +63.9% |
| 5 years ago · 18 Nov 2021 | ₹334.85 | +108.7% |
| 10 years ago · 18 Nov 2016 | ₹391.60 | +78.4% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹208.25 | +235.5% |
| Highest weekly close since February 2016, also the 52-week high · 13 Feb 2026 | ₹1,256.00 | −44.4% |
| Lowest weekly close since February 2016 · 3 Apr 2020 | ₹105.05 | +565.2% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹642.60 | +8.7% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
567 weekly closes from 26 February 2016 to 18 November 2026.
What is the latest news on Sharda Cropchem?
18 Nov 2026: Sharda Cropchem closed at ₹698.75, down 2.4% on the week and down 0.2% on the month. 2 Nov 2026: Sharda Cropchem held its results call for July to September 2026. Management guided: FY27 revenue growth 10-15%.
Earlier
- Results for July to September 2026: Revenue up 13.2% and profit up 24.3% on a year earlier.
- 7 Aug 2026: ex-date for a dividend of ₹9 a share.
- 6 Feb 2026: ex-date for an interim dividend of ₹6 a share.
What dividend does Sharda Cropchem pay?
Sharda Cropchem paid ₹15 a share in regular dividends in the 12 months to 18 November 2026 (2 payments), a yield of 2.15% at the ₹698.75 close on 18 November 2026. The last was a dividend of ₹9 a share, ex-date 7 August 2026.
Sharda Cropchem dividends since 1 April 2021
| Ex-date | Dividend per share | Type | Record date |
|---|---|---|---|
| 7 Aug 2026Dividend | ₹9 | Dividend | same day |
| 6 Feb 2026Interim | ₹6 | Interim | same day |
| 7 Aug 2025Dividend | ₹6 | Dividend | same day |
| 6 Feb 2025Interim | ₹3 | Interim | same day |
| 2 Aug 2024Dividend | ₹3 | Dividend | same day |
| 1 Aug 2023Dividend | ₹3 | Dividend | same day |
| 7 Feb 2023Interim | ₹3 | Interim | same day |
| 25 Jul 2022Dividend | ₹3 | Dividend | 26 Jul 2022 |
| 2 Feb 2022Interim | ₹3 | Interim | 3 Feb 2022 |
| 20 Jul 2021Dividend | ₹3 | Dividend | 22 Jul 2021 |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.
Yes. Sharda Cropchem Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.
From the exchange corporate-actions record, read 18 November 2026.
What did Sharda Cropchem management say on the latest results call?
On the call for July to September 2026, held on 2 November 2026, Sharda Cropchem's management guided: FY27 revenue growth 10-15%.
“We see this as a temporary, weather-led impact rather than any change in underlying demand.”R. V. Bubna, on the call for July to September 2026
What management guided
- FY27 operating margin 18-20% on better mix and operating leverage in second half.
- FY27 registration capital spending ₹550-600 crore backed by strong pipeline.
- Second-half operating margin above 20% to reach full-year low end.
- Europe to do well in seasonally stronger second half as conditions normalize.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 2 November 2026.
What to watch in Sharda Cropchem's next results?
When Sharda Cropchem reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Volume turn from price and mix-led growth - verify volume returns to growth and pricing improvement pace accelerates.
Management raised each of these on the latest results call.
- Volume turn from price and mix-led growth - verify volume returns to growth and pricing improvement pace accelerates.
- Registration spend discipline after arbitration overshoot - track quarterly spend against raised plan and pipeline conversion progress.
Which stock lists is Sharda Cropchem on?
Sharda Cropchem is on one of our India lists: Dividend stocks.
Is Sharda Cropchem profitable?
Sharda Cropchem Ltd earned ₹92.0 Cr of net profit in the Sep 2026 quarter, +24.3% on the same quarter a year earlier. Full-year FY26 profit was ₹681 Cr. Over 10 years profit has grown 14.6% a year on average. The Sep 2026 quarter's profit is 8.7% of that quarter's revenue. The same quarter a year earlier earned ₹74.0 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
For the full year, FY26 profit was ₹681 Cr (+124.0% on the year before).
Why profit moved: revenue changed +13.2% on a year earlier and the margin moved +1.3 percentage points. Sales did the work, and the margin was about flat.
On average over the last four quarters, profit changed +102.5% and revenue +18.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
How much revenue does Sharda Cropchem make, and is it growing?
Sharda Cropchem Ltd reported ₹1,052 Cr of revenue in the Sep 2026 quarter, +13.2% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 10 years it has grown 15.7% a year on average. The last full year, FY26, came in at ₹5,268 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. Europe accounts for ~45% of agrochemical sales and has the highest regional margin (42.5% gross margin in FY26 vs NAFTA 28%, LATAM 29%, Rest of World 37%). FY26 Europe volume grew ~16%. The EUR-USD cross-currency benefit added 10-11% to revenue growth, EUR was 1.04-1.03 vs USD a year ago vs 1.17 in FY26. Management guided similar Europe volume growth in FY27. NAFTA declined 6% in Q4 due to weather/US economic conditions, cited as non-structural.
The last four reported quarters add to ₹5,480 Cr.
FY26 revenue was ₹5,268 Cr, +21.9% on the year before.
Recent pace: the last four quarters grew +18.5% on average, against 15.7% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +17.3%, against +25.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +42.5%, against +72.3% a year (rolling over).
Watch next
- Metric
- Europe Volume Growth + EUR/USD Tailwind
- Threshold
- Q1 FY27 revenue print vs 10-15% annualized pace
- Which result
- the next result
How much of every ₹100 of sales does Sharda Cropchem keep?
Sharda Cropchem Ltd's operating margin was 15.6% in the Sep 2026 quarter, 1.3 percentage points higher than the same quarter a year ago. Across 13 years it has been between 9.6% and 23.2%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why this happened. Sharda's registration portfolio is the central competitive asset. As of March 31, 2026, the company has 3,011 product registrations across 70-75 countries (up from 2,994 as of Sep 2025 and 3,004 as of Dec 2025). The pipeline of 1,400 applications globally is the forward conversion funnel. Each registration approved creates a new revenue channel with pricing power from limited competition. Europe has 1,675 of the total (56% of registrations) with the highest gross margin at 42.5% in FY26. Management noted registrations process is highly uncertain (1-7 years) and FY27 growth does not solely depend on new molecule volumes.
Why the margin moved: operating margin changed +1.3 percentage points on the year while gross margin changed +1.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.
Watch next
- Metric
- Registration Moat + Pipeline Execution
- Threshold
- Q1 FY27 revenue print vs 10-15% annualized pace
- Which result
- the next result
Is Sharda Cropchem's profit turning into cash?
Over the last 3 years, 157% of Sharda Cropchem Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹656 Cr of operating cash against ₹681 Cr of profit. After ₹1.0 Cr of spending on assets, ₹655 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 157% of profit came in as cash: the cash cycle got 11 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.
What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.
Where does Sharda Cropchem's cash go?
Sharda Cropchem Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 125 days in FY26, up from 114 days in FY21. It spent ₹1.0 Cr on assets over the last 3 years. Customers take 166 days to pay, and stock sits for 121 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹5,268 Cr, each day of that cycle ties up about ₹14.4 Cr, so roughly ₹1,804 Cr is tied up in the business at any time.
FY26: customers took 166 days to pay and stock sat for 121 days, about 4.0 months of sales sitting as stock, for a full cycle of 125 days, longer than FY21's 114.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 121 days. Customers pay about 166 days after that. Suppliers are paid at 162 days. Together that makes the 125-day cycle.
Spending on assets: ₹1.0 Cr over the last 3 years, against ₹867 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹247 Cr (FY26): assets paid for that are not earning yet.
In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.
What is Sharda Cropchem's P/E ratio, and how does it compare with its own history?
Sharda Cropchem Ltd's P/E is 9.8×, about the lowest it has ever been. Its usual P/E (the middle reading) is 16.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why the multiple is where it is: over the past year earnings per share moved +42.4% while the price moved −12.6%. Earnings did better than the price, which pulled the multiple down within its own range.
Where the price move came from: over 3 years the price moved +17.9% a year; about +49.9% a year came from earnings growth and about −32.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.
Is the Sharda Cropchem business getting better or worse?
Sharda Cropchem Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +185.7% at its peak to +42.5%, but the business is still expanding, with ROCE rising at 27.9% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: when the lines disagree, each line above matters more than any single label.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +21.9% | +9.2% | +17.1% | +15.7% |
| Profit | +124.0% | +25.8% | +24.4% | +14.6% |
| EPS | +123.7% | +25.8% | +24.3% | +14.5% |
| Share price | −12.6% | +17.9% | +15.8% | +6.0% |
What is the Sharda Cropchem story, and has it been checked?
Sharda Cropchem Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: post peak earnings.
NOT YET CHECKED
Our read, 17 May 2026. Best-ever year in company history followed by a cautious guide-down, the margin story is real, but guidance credibility has a fresh crack.
From the numbers. The compression (-53%) is entirely earnings-driven: EPS tripled as earnings recovered from FY24 trough (Rs 3.53 EPS) to FY26…
From the price. Price stage 4, week 18, below its 200-day line, relative strength falling.
Where they disagree. The compression (-53%) is entirely earnings-driven: EPS tripled as earnings recovered from FY24 trough (Rs 3.53 EPS) to FY26 record (~Rs 75 EPS annualized).
The test written in advance. FY27 Revenue Guidance Step-Down Without Explanation. Measured by: FY27 Revenue Guidance Step-Down Without Explanation Q1 FY27 revenue print vs 10-15% annualized pace by the next result.
The test written in advance. EUR/USD Reversal Compresses Reported Margins. Measured by: EUR/USD Reversal Compresses Reported Margins EUR/USD rate + Q1 FY27 reported gross margin vs 35% band by the next result.
The test written in advance. NAFTA Structural Weakness vs Weather Narrative. Measured by: NAFTA Structural Weakness vs Weather Narrative Q1 FY27 NAFTA revenue trend + management tone by the next result.
What the company does. FY26 delivered best-ever revenue (Rs 5,268 Cr, +22% YoY), EBITDA (Rs 1,040 Cr, 19.7% margin, +69% YoY), and PAT (Rs 681 Cr, +124% YoY), a historic milestone off a deeply depressed FY24 base. The 3,011-registration moat + 1,400-application pipeline + 80-90% raw material pass-through pricing power underpin structural margin sustainability at 35% gross / 18-20% EBITDA for FY27. Management guided FY27 revenue only 10-15% (down from 15-20% Q3 commentary and well below FY26 actuals of 22%) without adequate explanation, creates material ambiguity and a guidance credibility watch.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters |
|---|---|---|
| Registration Moat + Pipeline Execution | HIGH | 3,011 total registrations + 1,400 pipeline applications, the moat expands every quarter as approvals convert, enabling volume… |
| Europe Volume Growth + EUR/ | HIGH | Europe drove FY26 agrochemical segment to +25% revenue with 16% volume growth and 42.5% gross margin, the single most important… |
| Pricing Power + Raw Material Pass-Through | HIGH | 80-90% raw material pass-through capability due to limited competition from registration barriers, structural margin protection… |
| Global Market Recovery + Inventory… | MEDIUM HIGH | Post-COVID inventory destocking fully normalized; global agrochemical demand revival after 18-24 months of channel correction… |
| Working Capital Efficiency | MEDIUM | Working capital improved from 118 days (FY25 high) to 98 days (FY26 end), 20-day release of capital improves FCF conversion and… |
| Non-Agrochemical Conveyor Belt Stability… | LOW MEDIUM | Rs 551 Cr segment (+1% FY26) with made-to-order model provides revenue stability and improving margins, but not a growth driver… |
Everything further down this page is evidence for or against these.
FY26-Q1FY26-Q4
- 1 · Operating leveragebuilding
- 2 · Value-added mixbuilding
- 3 · Management changequiet
- 4 · Paying down debtquiet
- 5 · Regulatory approvalquiet
- 6 · Order-book winsquiet
- 7 · Consolidationbuilding
- 8 · Demerger or value unlockquiet
- 9 · Buybackquiet
- 10 · New geographiesbuilding
- 11 · More business from existing customersquiet
- 12 · New product launchbuilding
- 13 · Mandatory normsquiet
- 14 · A bigger market to servebuilding
- 15 · Market-share gainsquiet
- 16 · Asset qualityquiet
Lever 2 · Value-added mix: building. 3,011 total registrations + 1,400 pipeline applications, the moat expands every quarter as approvals convert, enabling volume growth in new molecules and markets. What proves it keeps working: Registration Moat + Pipeline Execution. It stops working if Q1 FY27 revenue print vs 10-15% annualized pace.
Lever 10 · New geographies: building. Europe drove FY26 agrochemical segment to +25% revenue with 16% volume growth and 42.5% gross margin, the single most important profit driver in the portfolio. What proves it keeps working: Europe Volume Growth + EUR/USD Tailwind.
Lever 1 · Operating leverage: building. 80-90% raw material pass-through capability due to limited competition from registration barriers, structural margin protection that separates Sharda from commodity agchem players. What proves it keeps working: Pricing Power + Raw Material Pass-Through.
Lever 14 · A bigger market to serve: building. Post-COVID inventory destocking fully normalized; global agrochemical demand revival after 18-24 months of channel correction, provides volume floor across all regions. What proves it keeps working: Global Market Recovery + Inventory Normalization.
Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
Did Sharda Cropchem management deliver what it promised?
What Sharda Cropchem Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Europe Restocking Outlook Reversed · 2 November 2026. In Jul 2026, management described European distributor restocking as normalized and expected volume recovery in coming quarters. In Nov 2026, management said the weather-driven restocking problem had continued through September and distributors were still cautious. Although the latest call attributes this to extended heat and drought, it does not reconcile the reversal from the earlier normalization assessment.
Capex Assumption Changed Despite Prior No-Repeat Assurance · 2 November 2026. In Jul 2026, management said FY27 capex had not been revised and characterized the heavy Q1 data-compensation spending as non-recurring. In Nov 2026, management presented planned capex of Rs.550 to Rs.600 crores and reported Rs.419 crores spent in H1, while again citing unexpectedly high registration spending. The latest arbitration explanation is plausible, but management did not reconcile it with the prior statement that the exceptional spending would not repeat, creating a material cash deployment uncertainty.
FY27 Volume Growth Outlook Reduced · 30 July 2026. In May 2026, management indicated that FY27 volume growth should be around 15%. In the latest call in Jul 2026, management reduced the expected range to 5-10% without explaining the change, a material reduction that could affect the revenue growth outlook and operating assumptions.
FY26 EBITDA Margin Delivery Materially Exceeded Both Prior Guidance Ranges Without Explanation · 14 May 2026. Both prior calls consistently guided FY26 EBITDA margins at 15% to 18%, with the Oct 2025 call affirming management was on track for this range even after H1 FY26 delivered only 14.7% EBITDA margins. The Latest Call (May 2026) reports actual FY26 EBITDA margins of 19.7% - approximately 170 basis points above the top of the guided range - with Q4 FY26 alone reaching 24.8%. No explanation is offered for this material outperformance relative to guidance maintained consistently through two consecutive calls, and FY27 EBITDA guidance is now set at 18-20%, which remains below both the FY26 actual of 19.7% and the recent Q4 run rate of 24.8%, raising questions about guidance credibility.
Every quote above is taken word for word from the company’s own earnings calls.
How much does Sharda Cropchem earn on its capital?
Sharda Cropchem Ltd earned a ROCE of 30% in FY26. That is up from a low of 4% in FY24. Its return on capital used (ROIC) is 11.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.9% net margin and 0.92× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 12.9% net margin × 0.92× asset turnover × 1.84× leverage (assets divided by equity) ≈ 21.8% on equity. The margin does its share; borrowing is a big part of it.
The key test, return on capital used minus the cost of capital: 23.5% − 12.0% = +11.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 23.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 27.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does Sharda Cropchem have too much debt?
Sharda Cropchem Ltd has total debt of ₹24.0 Cr against shareholder equity of ₹3,250 Cr as of Sep 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
What is the Sharda Cropchem shareholding pattern?
Domestic institutions cut their stake in Sharda Cropchem Ltd by 3.5 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.2% of the company. Foreign institutions moved +0.8 points over the same period, to 3.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Over the last two years: Domestic institutions: −3.5 points over 8 quarters, to 9.2%; Foreign institutions: +0.8 points over 8 quarters, to 3.3%; Promoters: +0.0 points over 8 quarters, to 74.8%.
Why the owners changed: domestic institutions drove it (−3.5 points), with the other side taken by foreign institutions (+0.8 points). They reduced their stake.
How far is Sharda Cropchem from balance-sheet trouble?
For Sharda Cropchem Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Sharda Cropchem rank in its industry?
66.9 out of 100, rank 2 of 25 in Pesticides/Agrochemicals, with 100% of the evidence available.
Sharda Cropchem Ltd scores 66.9 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 2. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
The four parts add up to the total exactly: 28.2 + 19.6 + 11.5 + 7.6 = 66.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Sharda Cropchem compared with?
Sharda Cropchem ranks 2 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 66.9 out of 100.
- 1Titan Biotech Ltdbreaking out · Most evidence points up · 87% evidence76.6out of 100
How the score adds up
Growth & earnings 31.3/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 3 points · 95% evidenceCapital efficiency 21.3/25 · ROCE 22.8% (year to Mar 2026) · Operating margin 19.7% · 95% evidenceValuation 5.4/20 · P/E 55.2× · PEG — · 50% evidenceRelative strength 18.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 44.3% · Strength vs NIFTY 500 (same reading) 21.3% · 1 year 177.2% · 100% evidence · 4 of 12 weeks aheadExact sum: 31.3 + 21.3 + 5.4 + 18.6 = 76.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Sharda Cropchem Ltd this pageSHARDACROP · basing · Most evidence points up · 100% evidence66.9out of 100
How the score adds up
Growth & earnings 28.2/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 19.6/25 · ROCE 30.2% (year to Mar 2026) · Operating margin 15.6% · 100% evidenceValuation 11.5/20 · P/E 9.8× · PEG 2.28 · 100% evidenceRelative strength 7.6/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.2% · Strength vs NIFTY 500 (same reading) -21.1% · 1 year -12.6% · 100% evidence · 0 of 12 weeks aheadExact sum: 28.2 + 19.6 + 11.5 + 7.6 = 66.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 3Jubilant Ingrevia LtdJUBLINGREA · quiet · Most evidence points up · 93% evidence65.3out of 100
How the score adds up
Growth & earnings 27.4/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidenceCapital efficiency 13.8/25 · ROCE 11.4% (year to Mar 2026) · Operating margin 15.2% · 100% evidenceValuation 12.9/20 · P/E 26.7× · PEG 1.16 · 65% evidenceRelative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 3.8% · Strength vs NIFTY 500 (same reading) -13.5% · 1 year -18.5% · 100% evidence · 2 of 12 weeks aheadExact sum: 27.4 + 13.8 + 12.9 + 11.2 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 4Bayer CropScience LtdBAYERCROP · quiet · Evidence leans up · 85% evidence63.0out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue -5% · Profit 22.5% · Operating margin change 4 points · 100% evidenceCapital efficiency 19.3/25 · ROCE 29.1% (year to Mar 2026) · Operating margin 17.4% · 100% evidenceValuation 10.6/20 · P/E 20.2× · PEG 2.21 · 100% evidenceRelative strength 8.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -22.1% · 1 year -26.2% · 25% evidence · 0 of 12 weeks aheadExact sum: 24.5 + 19.3 + 10.6 + 8.6 = 63 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 5Dhanuka Agritech LtdDHANUKA · quiet · Evidence leans up · 100% evidence54.7out of 100
How the score adds up
Growth & earnings 10.0/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidenceCapital efficiency 19.8/25 · ROCE 25.9% (year to Mar 2026) · Operating margin 23.3% · 100% evidenceValuation 11.4/20 · P/E 14.8× · PEG 2.07 · 100% evidenceRelative strength 13.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.8% · Strength vs NIFTY 500 (same reading) -16.1% · 1 year -23.7% · 100% evidence · 0 of 12 weeks aheadExact sum: 10 + 19.8 + 11.4 + 13.5 = 54.7 · What this means: Relative strength against the index is -16.1%, and revenue and profit growth are weak. - 6Advance Agrolife LtdADVANCE · losing its lead · Evidence leans up · 68% evidence54.7out of 100
How the score adds up
Growth & earnings 19.0/35 · Revenue 49.4% · Profit 55.2% · Operating margin change -4 points · 100% evidenceCapital efficiency 13.7/25 · ROCE 19.6% (year to Mar 2026) · Operating margin 7.7% · 100% evidenceValuation 10.1/20 · P/E 17.4× · PEG — · 15% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 2.3% · 1 year -8.5% · 25% evidence · 10 of 12 weeks aheadExact sum: 19 + 13.7 + 10.1 + 11.9 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 7Punjab Chemicals & Crop Protection LtdPUNJABCHEM · quiet · Evidence leans up · 75% evidence53.0out of 100
How the score adds up
Growth & earnings 19.6/35 · Revenue 14% · Profit 13.2% · Operating margin change -1 points · 100% evidenceCapital efficiency 13.2/25 · ROCE 18.6% (year to Mar 2026) · Operating margin 9.2% · 100% evidenceValuation 11.0/20 · P/E 17.9× · PEG — · 50% evidenceRelative strength 9.2/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -19% · 1 year -34.1% · 25% evidence · 3 of 12 weeks aheadExact sum: 19.6 + 13.2 + 11 + 9.2 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Dharmaj Crop Guard LtdDHARMAJ · quiet · Evidence leans up · 75% evidence52.4out of 100
How the score adds up
Growth & earnings 14.5/35 · Revenue 3.8% · Profit 14.3% · Operating margin change -2 points · 100% evidenceCapital efficiency 14.7/25 · ROCE 16.8% (year to Mar 2026) · Operating margin 7.2% · 100% evidenceValuation 13.2/20 · P/E 15.1× · PEG — · 50% evidenceRelative strength 10.0/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -9.7% · 1 year -0.9% · 25% evidence · 5 of 12 weeks aheadExact sum: 14.5 + 14.7 + 13.2 + 10 = 52.4 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. - 9Best Agrolife LtdBESTAGRO · quiet · Evidence leans up · 90% evidence52.0out of 100
How the score adds up
Growth & earnings 24.7/35 · Revenue -19.6% · Profit 100% · Operating margin change 10 points · 100% evidenceCapital efficiency 10.0/25 · ROCE 5.2% (year to Mar 2026) · Operating margin 24.8% · 100% evidenceValuation 11.3/20 · P/E 10.8× · PEG — · 50% evidenceRelative strength 6.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -4.7% · Strength vs NIFTY 500 (same reading) -20.8% · 1 year -26.5% · 100% evidence · 7 of 12 weeks aheadExact sum: 24.7 + 10 + 11.3 + 6 = 52 · What this means: Earnings are strong; relative strength in its sector is -4.7% and the one-year return is -26.5%. - 10Meghmani Organics LtdMOL · quiet · Evidence leans down · 68% evidence49.7out of 100
How the score adds up
Growth & earnings 20.9/35 · Revenue -5.2% · Profit 100% · Operating margin change 2 points · 100% evidenceCapital efficiency 7.7/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 10.9% · 100% evidenceValuation 10.4/20 · P/E 15.6× · PEG — · 15% evidenceRelative strength 10.7/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -23.9% · 25% evidence · 8 of 12 weeks aheadExact sum: 20.9 + 7.7 + 10.4 + 10.7 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Excel Industries LtdEXCELINDUS · losing its lead · Evidence leans down · 68% evidence49.0out of 100
- 12UPL LtdUPL · basing · Evidence leans down · 82% evidence48.9out of 100
- 13Rallis India LtdRALLIS · quiet · Evidence leans down · 85% evidence47.9out of 100
- 14Shivalik Rasayan LtdSHIVALIK · turning · Evidence leans down · 67% evidence47.9out of 100
- 15Bhagiradha Chemicals & Industries LtdBHAGCHEM · quiet · Evidence leans down · 83% evidence47.7out of 100
- 16Epigral LtdEPIGRAL · quiet · Evidence leans down · 75% evidence46.8out of 100
- 17India Pesticides LtdIPL · quiet · Evidence leans down · 75% evidence46.0out of 100
- 18Sumitomo Chemical India LtdSUMICHEM · quiet · Evidence leans down · 85% evidence43.7out of 100
- 19Insecticides India LtdINSECTICID · quiet · Evidence leans down · 90% evidence42.8out of 100
- 20Bharat Rasayan LtdBHARATRAS · basing · Evidence leans down · 90% evidence42.4out of 100
- 21GSP Crop Science LtdGSPCROP · quiet · Evidence leans down · 63% evidence39.8out of 100
- 22P I Industries LtdPIIND · quiet · Most evidence points down · 75% evidence34.5out of 100
- 23NACL Industries LtdNACLIND · basing · Most evidence points down · 90% evidence32.9out of 100
- 24Heranba Industries LtdHERANBA · quiet · Most evidence points down · 71% evidence31.9out of 100
- 25Astec Lifesciences LtdASTEC · quiet · Most evidence points down · 71% evidence31.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pesticides/Agrochemicals, all 25 compared on one page.
Which companies are close to Sharda Cropchem in size?
Sharda Cropchem is the 6th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Sumitomo Chemical India, Bayer CropScience and Jubilant Ingrevia. Just below it: Dhanuka Agritech, Epigral and Rallis India.
Pesticides/Agrochemicals companies close in size
- Sumitomo Chemical India Ltd ₹16,684 crore
- Bayer CropScience Ltd ₹15,064 crore
- Jubilant Ingrevia Ltd ₹9,348 crore
- Sharda Cropchem Ltd ₹6,305 crore
- Dhanuka Agritech Ltd ₹4,173 crore
- Epigral Ltd ₹4,073 crore
- Rallis India Ltd ₹3,682 crore
All 25 Pesticides/Agrochemicals companies, largest first
Companies close in size in other industries
- Kirloskar Ferrous Industries Ltd ₹6,335 crore · Steel - Pig Iron
- Birla Corporation Ltd ₹6,320 crore · Cement
- Sharda Cropchem Ltd ₹6,305 crore
- Shrem InvIT ₹6,292 crore · Infrastructure Investment Trusts
- Dilip Buildcon Ltd ₹6,259 crore · EPC
What else do people ask about Sharda Cropchem?
What is Sharda Cropchem's share price today?
Sharda Cropchem Ltd's share price is ₹698.75, −12.6% over the past year. The whole company is worth ₹6,309 Cr on the market.
In the last 52 weeks it traded between ₹643 to ₹1,256; today it is 9% of the way up from the low, 15.5% below its 200-day average (as of 18 November 2026).
What were Sharda Cropchem's latest quarterly results?
Sharda Cropchem Ltd reported revenue of ₹1,052 Cr and net profit of ₹92.0 Cr for the Sep 2026 quarter. Revenue rose 13.2% and profit rose 24.3% compared with a year earlier. Earnings per share were ₹10.17.
The operating margin was 15.6%, 1.3 percentage points higher than a year earlier (as of 18 November 2026).
What is Sharda Cropchem's market cap?
Sharda Cropchem Ltd's market capitalisation is ₹6,309 Cr at a share price of ₹698.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
What is Sharda Cropchem's P/E ratio?
Sharda Cropchem Ltd's P/E is 9.8×, higher than 2% of its own last 11 years. Its usual level (the middle reading) is 16.8×. This compares the price with the company's own past; it is not a view on what the shares are worth (as of 18 November 2026).
How is Sharda Cropchem valued against its own history?
Against its own history, Sharda Cropchem Ltd's valuation is low: its P/E of 9.8× has been lower only 2% of the time in 11 years (usual level 16.8×).
This compares the price with the company's own past; it is not a view on what the shares are worth or where the price goes next (as of 18 November 2026).
How is Sharda Cropchem performing?
Sharda Cropchem Ltd's share price has been falling for 18 weeks. In its latest quarter, revenue rose 13.2% and profit rose 24.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 35 weeks running (as of 18 November 2026).
Will Sharda Cropchem's share price go up?
This page does not forecast Sharda Cropchem Ltd's share price. What it shows instead: the share price is ₹698.75, and it has been falling for 18 weeks. Its P/E of 9.8× is higher than 2% of its own last 11 years (as of 18 November 2026).
Who owns Sharda Cropchem?
Promoters own 74.8% of Sharda Cropchem Ltd, foreign institutions 3.3%, domestic institutions 9.2% and the public 12.7% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 3.5 percentage points over 8 quarters (as of 18 November 2026).
Where is Sharda Cropchem in its business cycle?
Sharda Cropchem Ltd's FY26 operating margin was 20.1%, against a 13-year range of 9.6% to 23.2%. The latest quarter was 15.6%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Sharda Cropchem story?
The main question: earnings per share (last four quarters) moved +42.4% while the share price moved −12.6%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Sharda Cropchem a stock worth studying right now?
What the numbers show: Sharda Cropchem Ltd's earnings have grown faster than its share price. Earnings per share grew +42.4% in a year while the price moved −12.6%. The main open question: whether the price catches up with earnings that have already grown.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Is there a Sharda Cropchem share price forecast for 2026?
What management itself guided: FY27 revenue growth 10-15%.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.